The drug is still in late-stage trials with a submission expected next year, yet more than a dozen Georgia medical facilities are already providing it.
Recap by typeshit. Post by Facebook on Facebook.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
An overview of trials on heart, kidney, liver, joints, lungs, mood and psoriasis, with notes on where evidence is still early or unproven.
Jonathan and Nir Zontag compared 438,474 diabetes patients on GLP-1 drugs with a matched group. New smell and taste problems were more common but still rare, they report in JAMA.
Loading…